Ruchi Chaudhary

Employment

• Johnson & Johnson

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (31)

• Data from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.c.8767718
  +Save
• Figure 1 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350659
  +Save
• Figure 2 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350653
  +Save
• Figure 3 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350650
  +Save
• Figure 4 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350647
  +Save
• Figure 5 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350644
  +Save
• Supplementary Figure S1 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350641
  +Save
• Supplementary Figure S2 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350638
  +Save
• Supplementary Figure S3 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350635
  +Save
• Supplementary Figure S4 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350632
  +Save
• Supplementary Figure S5 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350629
  +Save
• Supplementary Figure S6 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350626
  +Save
• Supplementary Figure S7 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350623
  +Save
• Supplementary Table S1 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350620
  +Save
• Supplementary Table S2 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350617
  +Save
• Table 1 from Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  2026 DOI: 10.1158/2767-9764.34350614
  +Save
• Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer
  Cancer Research Communications 2026 DOI: 10.1158/2767-9764.CRC-26-0477
  +Save
• Data from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
  2025 DOI: 10.1158/1078-0432.c.8125980
  +Save
• Figure 1 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
  2025 DOI: 10.1158/1078-0432.30516303
  +Save
• Figure 2 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
  2025 DOI: 10.1158/1078-0432.30516300
  +Save